Details

Autor(en) / Beteiligte

• Huang, Jinghe
• Kang, Byong H.
• Ishida, Elise
• Zhou, Tongqing
• Griesman, Trevor
• Sheng, Zizhang
• Wu, Fan
• Doria-Rose, Nicole A.
• Zhang, Baoshan
• McKee, Krisha
• O’Dell, Sijy
• Chuang, Gwo-Yu
• Druz, Aliaksandr
• Georgiev, Ivelin S.
• Schramm, Chaim A.
• Zheng, Anqi
• Joyce, M. Gordon
• Asokan, Mangaiarkarasi
• Ransier, Amy
• Darko, Sam
• Migueles, Stephen A.
• Bailer, Robert T.
• Louder, Mark K.
• Alam, S. Munir
• Parks, Robert
• Kelsoe, Garnett
• Von Holle, Tarra
• Haynes, Barton F.
• Douek, Daniel C.
• Hirsch, Vanessa
• Seaman, Michael S.
• Shapiro, Lawrence
• Mascola, John R.
• Kwong, Peter D.
• Connors, Mark

Titel

Identification of a CD4-Binding-Site Antibody to HIV that Evolved Near-Pan Neutralization Breadth

Ist Teil von

• Immunity (Cambridge, Mass.), 2016-11, Vol.45 (5), p.1108-1121

Ort / Verlag

United States: Elsevier Inc

Erscheinungsjahr

2016

Link zum Volltext

Quelle

Free E-Journal (出版社公開部分のみ）

Beschreibungen/Notizen

• Detailed studies of the broadly neutralizing antibodies (bNAbs) that underlie the best available examples of the humoral immune response to HIV are providing important information for the development of therapies and prophylaxis for HIV-1 infection. Here, we report a CD4-binding site (CD4bs) antibody, named N6, that potently neutralized 98% of HIV-1 isolates, including 16 of 20 that were resistant to other members of its class. N6 evolved a mode of recognition such that its binding was not impacted by the loss of individual contacts across the immunoglobulin heavy chain. In addition, structural analysis revealed that the orientation of N6 permitted it to avoid steric clashes with glycans, which is a common mechanism of resistance. Thus, an HIV-1-specific bNAb can achieve potent, near-pan neutralization of HIV-1, making it an attractive candidate for use in therapy and prophylaxis. •CD4bs antibody N6 potently neutralizes 98% of HIV isolates•N6 potently neutralizes isolates resistant to other CD4bs antibodies•N6 evolved from an early intermediate within a VRC01-class antibody lineage•Unique structural features circumvent mechanisms of resistance to the VRC01 class Detailed studies of broadly neutralizing antibodies are providing important information for the development of therapies, prophylaxis, and vaccines for HIV-1. Huang et al. report a CD4-binding-site antibody that evolved to circumvent common mechanisms of resistance, resulting in an antibody that achieves potent, near-pan neutralization of HIV-1.